Currently, a fully human monoclonal IgG1 antibody, Burosumab, is under investigation for rare diseases with primary FGF23 excess and the clinical picture of phosphate-losing osteomalacia (X-linked hypophosphatemia). The gene discussed is FGF23; the disease is X-linked hypophosphatemia.